Immune and Genomic Markers in ALK+ NSCLC

Related Clinical Trial
A Dose-Escalation/ Dose-Expansion Study of SY-3505 in Patients With ALK-positive Non-small Cell Lung Cancer Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients Patient-centered, Optimal Integration of Survivorship and Palliative Care Immune and Genomic Markers in ALK+ NSCLC Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India An Observational Research Of Crizotinib’s Hepatic Toxicity In Non-small Cell Lung Cancer Patients Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

Brief Title

Immune and Genomic Markers in ALK+ NSCLC

Official Title

Elucidating Novel Immune and Genomic Markers for ALK (ENIGMA+)

Brief Summary

      The purpose of this research study is to obtain and study clinical history, and tissue and
      saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK+
      Non-Small Lung Cancer(NSCLC)

Detailed Description

      The purpose of this study is to establish a registry of clinical data and tumor specimens of
      patients with advanced ALK+ non-small lung cancer (NSCLC) (defined as NSCLC harboring an ALK
      gene rearrangement). This will allow in-depth, comprehensive genomic and immunophenotypic
      analyses of ALK+ tumors. Together with the clinical data, these biologic specimens will
      enable the conduct of basic and translational research to identify genomic and immunologic
      markers associated with clinical outcomes for ALK+ patients.

Study Type

Observational [Patient Registry]

Primary Outcome

Registry Establishment

Secondary Outcome

 Duration Of Therapy


Anaplastic Lymphoma Kinase Gene Translocation

Study Arms / Comparison Groups

 Sample Collection
Description:  Participation In:
Initial data completion: Telephone collection of information on disease, treatment and testing
Medical record collection: Collection of medical records regarding cancer, testing, and treatment history
Archival tissue collection: Collection of tumor from prior standard of care procedure
Saliva collection: Saliva collection with at home kit
Follow up data completion: Telephone collection of medical condition every 3-6 months up to 2 years.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

December 1, 2021

Completion Date

December 1, 2025

Primary Completion Date

December 1, 2025

Eligibility Criteria

        Inclusion Criteria:

        Cohort 1 - Alive Individuals

          -  Men or women 18 years of age or the age of majority for their residential state of the
             United States, or older, at the time of consent.

          -  Histologically or cytologically confirmed advanced stage IIIB-IIIC not amenable to
             curative approach multi-modality (e.g., chemoradiation and/or surgery) treatment, or
             stage IV non-small cell lung cancer (NSCLC)

          -  Demonstration of having advanced ALK+ NSCLC, as assessed by fluorescence in situ
             hybridization (FISH), immunohistochemistry (IHC), next-generation sequencing (NGS) or
             circulating tumor DNA analysis (ctDNA). For ALK FISH, fusions must have been detected
             in at least 15% of tumor cells.

          -  Willingness to provide clinical and medical information to the study team as required.

          -  Willingness to provide archival tumor tissue, if available. Patients may enroll even
             if no tumor tissue is available.

          -  Ability to read, write and communicate in English.

          -  Ability to sign a web-based informed consent form.

        Cohort 2 - Deceased Individuals

          -  Deceased individuals diagnosed with advanced ALK+ lung cancer at age 18 years or older
             may be studied on a case by case basis. Inclusion will require availability of
             adequate archived tissue and release of tissue and records by next of kin, if

        Exclusion Criteria:

          -  Participants who are unwilling to provide informed consent.

          -  Participants who are younger than 18 years of age.

          -  Participants who are unable to comply with the study procedures.

          -  Known existence of an uncontrolled intercurrent illness including, but not limited to,
             psychiatric illness or social situations that would impair compliance with study

          -  Participants who have previously enrolled to the study.




18 Years - N/A

Accepts Healthy Volunteers



Jessica J Lin, MD, 617-724-4000, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Massachusetts General Hospital


 Lungevity Foundation

Study Sponsor

Jessica J Lin, MD, Principal Investigator, Massachusetts General Hospital

Verification Date

January 2022